SlideShare a Scribd company logo
5-Year Survival of Gastric Cancer Patients after Radical
Surgery was Significantly Depended on Tumor Characteristics,
Blood Cell Circuit, Cell Ratio Factors, Hemostasis System
and Adjuvant Treatment
OBJECTIVE: This study aimed to determine homeostasis and tumor
factors for 5-year survival (5YS) of gastric cancer (GC) patients (GCP) (T1-
4N0-2M0) after complete en block (R0) gastrectomies and D2-4 lymph
node dissections.
METHODS: We analyzed data of 715 consecutive GCP (age=57.1±9.6
years; tumor size-D=5.6±3.1 cm) radically operated (R0) and monitored in
1975-2015 (m=488, f=227; total gastrectomy=145, distal gastrectomy=420,
proximal gastrectomy=150, combined gastrectomy with resection of 1-6
adjacent organs (pancreas, liver, diaphragm, colon transversum,
splenectomy, small intestine, kidney, adrenal gland, etc.)=232; T1=196,
T2=203, T3=167, T4=149; M1=0; N0=376, N1=100, N2=239; G1=199,
G2=132, G3=384; early GC=125, invasive GC=590; only surgery-S=569,
adjuvant treatment-AT=146 (chemoimmunotherapy: 5-FU +
thymalin/taktivin). Survival curves were estimated by the Kaplan-Meier
method. Differences in curves between groups of GCP were evaluated
using a log-rank test. Cox modeling, clustering, SEPATH, Monte Carlo,
bootstrap simulation and neural networks computing were used to
determine any significant dependence.
RESULTS: For total of 715 GCP overall life span (LS) was 2060.6±2267.7
days, (median=1022 days) and cumulative 5-year survival (5YS) reached
55.1%, 10 years – 48.7%, 20 years – 37.6%. 272 GCP lived more than 5
years without GC progressing, 149 – 10 years, 35 - 20 years. 281 GCP died
because of GC during the first 5 years after surgery. 5YS was superior
significantly after AT (69.8%) compared with S (52.4%) (P=0.002 by log-
rank test). Cox modeling displayed that 5YS significantly depended on:
phase transition (PT) early-invasive GC in term of synergetics, PT N0-N12,
G, blood cell circuit, cell ratio factors (CRF) (ratio between cancer cells
and blood cells subpopulations), sex, AT, residual nitrogen, hemorrhage
time, prothrombin index, procedure type (P=0.000-0.048). Neural networks
computing, genetic algorithm selection and bootstrap simulation revealed
relationships between 5YS and PT early-invasive GC (rank=1), PT N0-N12
(rank=2), D (3), erythrocytes/cancer cells-CC (4), AT (5), healthy cells/CC
(6), prothrombin index (7), thrombocytes/cancer cells (8), monocytes/CC
(9), stick neutrophils/CC (10), eosinophils/CC (11), leucocytes/CC (12),
segmented neutrophils/CC (13), lymphocytes/CC (14). Correct prediction
of 5YS was 100% by neural networks computing.
CONCLUSIONS: 5YS of GCP after radical surgery was significantly
depended on tumor characteristics, blood cell circuit, CRF, hemostasis
system and AT.
Oleg Kshivets, MD, PhD Surgery Department, Medical Center, Anapa, Russia P-258
Cox Regression
Parameter
Estimate
Standard
Error
Chi-square P value
95%
Lower CL
95%
Upper CL
Hazard Ratio
Eosinophils (%) -0.54001 0.263410 4.20278 0.040358 -1.0563 -0.02373 0.583
Segmented Neutrophils (%) -0.48036 0.247618 3.76331 0.052389 -0.9657 0.00496 0.619
Lymphocytes (%) -0.49636 0.251277 3.90206 0.048227 -0.9889 -0.00387 0.609
ESS -0.01579 0.005293 8.90242 0.002848 -0.0262 -0.00542 0.984
Hemorrhage Time 0.00123 0.000391 9.87506 0.001675 0.0005 0.00199 1.001
Residual Nitrogen 0.04625 0.009859 22.00602 0.000003 0.0269 0.06557 1.047
Prothrombin Index 0.01794 0.005229 11.77447 0.000600 0.0077 0.02819 1.018
PT N0---N12 0.81004 0.132049 37.63086 0.000000 0.5512 1.06885 2.248
Sex 0.34302 0.127690 7.21628 0.007225 0.0927 0.59329 1.409
G1-3 0.14158 0.069223 4.18338 0.040822 0.0059 0.27726 1.152
Adjuvant Chemoimmunotherapy -0.74498 0.196078 14.43549 0.000145 -1.1293 -0.36067 0.475
PT Early---Invasive Cancer 1.05392 0.339457 9.63932 0.001905 0.3886 1.71924 2.869
Leucocytes (tot) -3.97989 1.108824 12.88300 0.000332 -6.1531 -1.80664 0.019
Eosinophils (tot) 4.35950 1.145350 14.48761 0.000141 2.1147 6.60434 78.218
Stick Neutrophils (tot) 3.72513 1.090917 11.66003 0.000639 1.5870 5.86329 41.477
Segmented Neutrophils (tot) 3.98772 1.105228 13.01803 0.000309 1.8215 6.15393 53.932
Lymphocytes (tot) 3.96596 1.116264 12.62298 0.000381 1.7781 6.15379 52.771
Monocytes (tot) 4.24914 1.155433 13.52425 0.000236 1.9845 6.51375 70.045
Thrombocytes/CC 0.00138 0.000685 4.07046 0.043639 0.0000 0.00272 1.001
Leucocytes/CC 8.12117 2.770057 8.59527 0.003370 2.6920 13.55038 3364.943
Eosinophils/CC -9.36552 2.878071 10.58913 0.001138 -15.0064 -3.72460 0.000
Stick Neutrophils/CC -7.58172 2.883567 6.91314 0.008556 -13.2334 -1.93003 0.001
Segmented Neutrophils/CC -8.23960 2.783007 8.76564 0.003070 -13.6942 -2.78500 0.000
Lymphocytes/CC -8.01138 2.756945 8.44421 0.003662 -13.4149 -2.60787 0.000
Monocytes/CC -9.46646 3.001900 9.94449 0.001613 -15.3501 -3.58284 0.000
Operation Type 0.16080 0.077795 4.27221 0.038741 0.0083 0.31327 1.174
Stick Neutrophils (%) -0.45056 0.246290 3.34666 0.067342 -0.9333 0.03216 0.637
Monocytes (%) -0.46372 0.261830 3.13667 0.076550 -0.9769 0.04946 0.629
Neural Networks:
Baseline Error=0.000;
Area under ROC Curve=1.000;
Correct Classification Rate=100%
Rank Sensitivity
PT Early---Invasive Cancer 1 11004
PT N0---N12 2 10821
Tumor Size 3 8971
Erythrocytes/Cancer Cells 4 6231
Adjuvant Chemoimmunotherapy 5 5762
Healthy Cells/Cancer Cells 6 5558
Prothrombin Index 7 3778
Thrombocytes/Cancer Cells 8 3350
Monocytes/Cancer Cells 9 2884
Stick Neutrophils/Cancer Cells 10 2799
Eosinophils/Cancer Cells 11 2302
Leucocytes/Cancer Cells 12 1981
Segmented Neutrophils/ Cancer Cells 13 1714
Lymphocytes/Cancer Cells 14 1474
Bootstrap Simulation Rank Kendall’Tau-A P<
PT N0---N12 1 -0.206 0.000
Tumor Size 2 -0.200 0.000
Residual Nitrogen 3 -0.188 0.000
T1-4 4 -0.185 0.000
PT Early---Invasive Cancer 5 -0.162 0.000
Healthy Cells/Cancer Cells 6 0.157 0.000
Leucocytes/Cancer Cells 7 0.150 0.000
Lymphocytes/Cancer Cells 8 0.136 0.000
Seg.Neutrophils/Cancer Cells 9 0.135 0.000
Erythrocytes/Cancer Cells 10 0.134 0.000
Tumor Growth 11 -0.127 0.000
Thrombocytes/Cancer Cells 12 0.126 0.000
Localization 13 -0.109 0.000
Coagulation Time 14 -0.108 0.000
Chlorides 15 0.106 0.000
G1-3 16 -0.102 0.000
Monocytes/Cancer Cells 17 0.092 0.01
Operation Type 18 -0.079 0.01
Histology 19 -0.073 0.01
ESS 20 0.071 0.05
Prothrombin Index 21 0.067 0.05
Glucose 22 0.065 0.05

More Related Content

What's hot

Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Oleg Kshivets
 
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryKshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryOleg Kshivets
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Oleg Kshivets
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018Oleg Kshivets
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Oleg Kshivets
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Oleg Kshivets
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Oleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019Oleg Kshivets
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisOleg Kshivets
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021Oleg Kshivets
 

What's hot (20)

Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018
 
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
 
Kshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryKshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer Surgery
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets IASLC 2019
Kshivets IASLC 2019Kshivets IASLC 2019
Kshivets IASLC 2019
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
 

Similar to Kshivets barcelona2016

Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Oleg Kshivets
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020Oleg Kshivets
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...Oleg Kshivets
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivetsOleg Kshivets
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Oleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise PredictionOleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfOleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfOleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryOleg Kshivets
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfOleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Oleg Kshivets
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017Oleg Kshivets
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Oleg Kshivets
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors Oleg Kshivets
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Oleg Kshivets
 

Similar to Kshivets barcelona2016 (20)

Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
 
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
Esophageal Cancer: Artificial Intelligence, Synergetics, Complex System Analy...
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 

More from Oleg Kshivets

Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfOleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfOleg Kshivets
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfOleg Kshivets
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Oleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction Oleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrOleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021Oleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival Oleg Kshivets
 

More from Oleg Kshivets (12)

Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 

Recently uploaded

Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerSherrylee83
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingMedicoseAcademics
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...KavyasriPuttamreddy
 
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdfรายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdfVorawut Wongumpornpinit
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxdrwaque
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxSergio Pinski
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale nowSherrylee83
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Anjali Parmar
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionGolden Helix
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)Monika Kanwar
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...PhRMA
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communicationskatiequigley33
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartMedicoseAcademics
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyDr KHALID B.M
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediatesdorademei
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Catherine Liao
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feeldranji1
 
CNN-based plastic waste detection system
CNN-based plastic waste detection systemCNN-based plastic waste detection system
CNN-based plastic waste detection systemBOHRInternationalJou1
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxDr. Rabia Inam Gandapore
 

Recently uploaded (20)

Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdfรายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
CNN-based plastic waste detection system
CNN-based plastic waste detection systemCNN-based plastic waste detection system
CNN-based plastic waste detection system
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
 

Kshivets barcelona2016

  • 1. 5-Year Survival of Gastric Cancer Patients after Radical Surgery was Significantly Depended on Tumor Characteristics, Blood Cell Circuit, Cell Ratio Factors, Hemostasis System and Adjuvant Treatment OBJECTIVE: This study aimed to determine homeostasis and tumor factors for 5-year survival (5YS) of gastric cancer (GC) patients (GCP) (T1- 4N0-2M0) after complete en block (R0) gastrectomies and D2-4 lymph node dissections. METHODS: We analyzed data of 715 consecutive GCP (age=57.1±9.6 years; tumor size-D=5.6±3.1 cm) radically operated (R0) and monitored in 1975-2015 (m=488, f=227; total gastrectomy=145, distal gastrectomy=420, proximal gastrectomy=150, combined gastrectomy with resection of 1-6 adjacent organs (pancreas, liver, diaphragm, colon transversum, splenectomy, small intestine, kidney, adrenal gland, etc.)=232; T1=196, T2=203, T3=167, T4=149; M1=0; N0=376, N1=100, N2=239; G1=199, G2=132, G3=384; early GC=125, invasive GC=590; only surgery-S=569, adjuvant treatment-AT=146 (chemoimmunotherapy: 5-FU + thymalin/taktivin). Survival curves were estimated by the Kaplan-Meier method. Differences in curves between groups of GCP were evaluated using a log-rank test. Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap simulation and neural networks computing were used to determine any significant dependence. RESULTS: For total of 715 GCP overall life span (LS) was 2060.6±2267.7 days, (median=1022 days) and cumulative 5-year survival (5YS) reached 55.1%, 10 years – 48.7%, 20 years – 37.6%. 272 GCP lived more than 5 years without GC progressing, 149 – 10 years, 35 - 20 years. 281 GCP died because of GC during the first 5 years after surgery. 5YS was superior significantly after AT (69.8%) compared with S (52.4%) (P=0.002 by log- rank test). Cox modeling displayed that 5YS significantly depended on: phase transition (PT) early-invasive GC in term of synergetics, PT N0-N12, G, blood cell circuit, cell ratio factors (CRF) (ratio between cancer cells and blood cells subpopulations), sex, AT, residual nitrogen, hemorrhage time, prothrombin index, procedure type (P=0.000-0.048). Neural networks computing, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive GC (rank=1), PT N0-N12 (rank=2), D (3), erythrocytes/cancer cells-CC (4), AT (5), healthy cells/CC (6), prothrombin index (7), thrombocytes/cancer cells (8), monocytes/CC (9), stick neutrophils/CC (10), eosinophils/CC (11), leucocytes/CC (12), segmented neutrophils/CC (13), lymphocytes/CC (14). Correct prediction of 5YS was 100% by neural networks computing. CONCLUSIONS: 5YS of GCP after radical surgery was significantly depended on tumor characteristics, blood cell circuit, CRF, hemostasis system and AT. Oleg Kshivets, MD, PhD Surgery Department, Medical Center, Anapa, Russia P-258 Cox Regression Parameter Estimate Standard Error Chi-square P value 95% Lower CL 95% Upper CL Hazard Ratio Eosinophils (%) -0.54001 0.263410 4.20278 0.040358 -1.0563 -0.02373 0.583 Segmented Neutrophils (%) -0.48036 0.247618 3.76331 0.052389 -0.9657 0.00496 0.619 Lymphocytes (%) -0.49636 0.251277 3.90206 0.048227 -0.9889 -0.00387 0.609 ESS -0.01579 0.005293 8.90242 0.002848 -0.0262 -0.00542 0.984 Hemorrhage Time 0.00123 0.000391 9.87506 0.001675 0.0005 0.00199 1.001 Residual Nitrogen 0.04625 0.009859 22.00602 0.000003 0.0269 0.06557 1.047 Prothrombin Index 0.01794 0.005229 11.77447 0.000600 0.0077 0.02819 1.018 PT N0---N12 0.81004 0.132049 37.63086 0.000000 0.5512 1.06885 2.248 Sex 0.34302 0.127690 7.21628 0.007225 0.0927 0.59329 1.409 G1-3 0.14158 0.069223 4.18338 0.040822 0.0059 0.27726 1.152 Adjuvant Chemoimmunotherapy -0.74498 0.196078 14.43549 0.000145 -1.1293 -0.36067 0.475 PT Early---Invasive Cancer 1.05392 0.339457 9.63932 0.001905 0.3886 1.71924 2.869 Leucocytes (tot) -3.97989 1.108824 12.88300 0.000332 -6.1531 -1.80664 0.019 Eosinophils (tot) 4.35950 1.145350 14.48761 0.000141 2.1147 6.60434 78.218 Stick Neutrophils (tot) 3.72513 1.090917 11.66003 0.000639 1.5870 5.86329 41.477 Segmented Neutrophils (tot) 3.98772 1.105228 13.01803 0.000309 1.8215 6.15393 53.932 Lymphocytes (tot) 3.96596 1.116264 12.62298 0.000381 1.7781 6.15379 52.771 Monocytes (tot) 4.24914 1.155433 13.52425 0.000236 1.9845 6.51375 70.045 Thrombocytes/CC 0.00138 0.000685 4.07046 0.043639 0.0000 0.00272 1.001 Leucocytes/CC 8.12117 2.770057 8.59527 0.003370 2.6920 13.55038 3364.943 Eosinophils/CC -9.36552 2.878071 10.58913 0.001138 -15.0064 -3.72460 0.000 Stick Neutrophils/CC -7.58172 2.883567 6.91314 0.008556 -13.2334 -1.93003 0.001 Segmented Neutrophils/CC -8.23960 2.783007 8.76564 0.003070 -13.6942 -2.78500 0.000 Lymphocytes/CC -8.01138 2.756945 8.44421 0.003662 -13.4149 -2.60787 0.000 Monocytes/CC -9.46646 3.001900 9.94449 0.001613 -15.3501 -3.58284 0.000 Operation Type 0.16080 0.077795 4.27221 0.038741 0.0083 0.31327 1.174 Stick Neutrophils (%) -0.45056 0.246290 3.34666 0.067342 -0.9333 0.03216 0.637 Monocytes (%) -0.46372 0.261830 3.13667 0.076550 -0.9769 0.04946 0.629 Neural Networks: Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100% Rank Sensitivity PT Early---Invasive Cancer 1 11004 PT N0---N12 2 10821 Tumor Size 3 8971 Erythrocytes/Cancer Cells 4 6231 Adjuvant Chemoimmunotherapy 5 5762 Healthy Cells/Cancer Cells 6 5558 Prothrombin Index 7 3778 Thrombocytes/Cancer Cells 8 3350 Monocytes/Cancer Cells 9 2884 Stick Neutrophils/Cancer Cells 10 2799 Eosinophils/Cancer Cells 11 2302 Leucocytes/Cancer Cells 12 1981 Segmented Neutrophils/ Cancer Cells 13 1714 Lymphocytes/Cancer Cells 14 1474 Bootstrap Simulation Rank Kendall’Tau-A P< PT N0---N12 1 -0.206 0.000 Tumor Size 2 -0.200 0.000 Residual Nitrogen 3 -0.188 0.000 T1-4 4 -0.185 0.000 PT Early---Invasive Cancer 5 -0.162 0.000 Healthy Cells/Cancer Cells 6 0.157 0.000 Leucocytes/Cancer Cells 7 0.150 0.000 Lymphocytes/Cancer Cells 8 0.136 0.000 Seg.Neutrophils/Cancer Cells 9 0.135 0.000 Erythrocytes/Cancer Cells 10 0.134 0.000 Tumor Growth 11 -0.127 0.000 Thrombocytes/Cancer Cells 12 0.126 0.000 Localization 13 -0.109 0.000 Coagulation Time 14 -0.108 0.000 Chlorides 15 0.106 0.000 G1-3 16 -0.102 0.000 Monocytes/Cancer Cells 17 0.092 0.01 Operation Type 18 -0.079 0.01 Histology 19 -0.073 0.01 ESS 20 0.071 0.05 Prothrombin Index 21 0.067 0.05 Glucose 22 0.065 0.05